Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 3

1(25.0%)

Phase 1

1(25.0%)

4Total

N/A(2)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT07456813Not ApplicableNot Yet Recruiting

Clinical Study on Guben Kechuan Granules Promoting Disease Recovery by Regulating Immune-Inflammatory Dysregulation in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease During the Peri-Discharge Period

Role: collaborator

NCT07403032Not ApplicableNot Yet Recruiting

Study on the Effects and Mechanisms of Modified Ma Xing Shi Gan Decoction in Treating Acute Exacerbations of Chronic Obstructive Pulmonary Disease

Role: collaborator

NCT05993884Phase 1Completed

Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke

Role: collaborator

NCT05159947Phase 3Unknown

SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial

Role: collaborator

All 4 trials loaded